Viking Therapeutics (VKTX) Announces New, Statistically Significant Data from VK2809 Phasae 1b in Hypercholesterolemia
Tweet Send to a Friend
Viking Therapeutics, Inc. (Nasdaq: VKTX) announced additional data from its previously completed Phase 1b clinical trial of VK2809 in subjects ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
